1 terminated. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Recursion Pharmaceuticals Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas REC-2282, Placebo - Neurofibromatosis Type 2 | Phase 2 / Phase 3 | Terminated | Recursion Pharmaceuticals Inc. | 25 | 2022-06-20 | 2026-08-17 |
HDAC-42 (1)
United Kingdom (1) · United States (1)